The companies aiming to take advantage of patent expiries of some of the world’s best-selling biologics – be they the Sandoz unit of Swiss pharma giant Novartis 5 August 2016
From its academic origins to its innovative assets, bold business strategy and the targeting of an unmet need, Chronos Therapeutics is the sort of company which 28 July 2016
Having spent 24 years working closely with pharma companies and regulators for one of the industry’s leading contract research organizations (CROs), Alberto Gri 25 July 2016
The race to come up with a biosimilar version of the rheumatoid arthritis treatment Humira (adalimumab) – the world’s top-selling drug – is well and truly on. 18 July 2016
The head of Eisai (TYO: 4523) in Europe has pledged to subsidize the cost of thyroid cancer drug Lenvima (lenvatinib) if health bosses agree to include it in th 14 July 2016
Novartis (NOVN.VX) might have a long heritage in leading antimalarial drug development.but there is now an awareness that it faces a major new challenge in brin 5 July 2016
It is no secret that companies which are able to successfully develop biosimilar versions of big-selling biologics in the next five to 10 years will be onto a g 1 July 2016
Jennifer Miller is the founding president of Bioethics International (BEI), a US-based non-profit organization which aims to improve the ethics and transparency 29 June 2016
The boss of one of Europe’s leading biotech companies tells The Pharma Letter that it cannot now consider teaming up with UK researchers because of fears that s 27 June 2016
UK-based Sinclair Pharma has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months. 25 June 2016
The biosimilars pipeline of the South Korean company Samsung Bioepis would be highly impressive if it belonged to a long-established, world-leading pharma giant 22 June 2016
There has been a lot of excitement about the potential of biosimilars at the European League Against Rheumatism Annual Congress (EULAR) in London this week. 10 June 2016
If the back-to-biology approach being championed by Boston-based biopharma company Berg delivers to patients what it promises to, then it could spell the end fo 31 May 2016
Keith Thompson.the chief executive of the Cell and Gene Therapy Catapult (CGT).tells TPL's Guy Martin that the launch of Islexa UK.a company aimed at bringing i 23 May 2016
It goes without saying that being successful in pharma requires innovation, particularly with a number of big companies facing damaging patent expirations in th 23 May 2016
Following news this week that Cardiff-based cell therapy company Cell Therapy Ltd (CTL) has signed a partnership agreement giving Japan’s Daiichi Sankyo the rig 11 May 2016
Achieving commercial success and leading new innovations at the same time as proving your credentials as ethical, patient-focused and community-minded is what s 9 May 2016
Stephen O’Hara is chief executive of OptiBiotix Health, a UK-based biotech which has been interesting big pharma recently with its Lactobacillus plantarum strai 4 May 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.